Preface

 In the tide of biological manufacturing and regenerative medicine, opportunities and challenges coexist. Recently, the core team of QINGDAO AMA Co.,LTD. went to Hainan and started a journey of in-depth visits and ideological collision. During our eight day trip to Hainan, we went deep into the forefront of China's medical opening-up and had in-depth exchanges with policy makers and clinical experts to draw a clearer and more confident blueprint for the clinical application of the disruptive technology - "scaffold free cell live tablets".

Grand event set off: drawing a new picture of biological manufacturing

 On December 20, executive director meiyonghong of Huada group, Professor shidayong of Shandong University, Professor tianxiwei of East China University of science and technology and general manager wangenxu of Huaxi biology delivered speeches around the macro development, key technology breakthroughs and industrialization path of biological manufacturing, presenting the whole chain picture from "technology" to "product". Dr Fang's 2025 report on key equipment and process innovation for synthetic biological manufacturing focuses on "hard technology" innovation in the upper reaches of the industry and provides an important reference for the development of our company's new products.

 On December 21, at a meeting led by Professor Xia Jianye of Tianjin Institute of industrial biotechnology, Chinese Academy of Sciences and Professor Mao Xiangchao of Ocean University of China, many enterprises and research institutions jointly explored the latest progress and transformation path. At the meeting, President Han Xiao of yazhouwan science and technology city administration further clarified the policy path and industrial opportunities for enterprises to land and develop in Hainan, providing clear layout guidance for participating enterprises.

On this high-level professional platform, QINGDAO AMA Co.,LTD., as an enterprise representative, conducted a roadshow, which focused on the disruptive technology of self-developed "scaffold free cell live tablets" to the participating experts and industry colleagues. It triggered high interest and active discussion among experts and industry insiders, and further consolidated the technology leading image of Jindian on the regenerative medicine segment.

Entering Yazhou Bay: Unlock the password of deep sea and seeds

On December 22, the team went to the front line of scientific research and visited bases such as the China University of Oceanography, yazhouwan science and Technology City, Hainan Research Institute of Shanghai Jiao Tong University, and felt the great potential of the cross integration of deep-sea science and life sciences.

Toread Music City: Medical openness and new biomedical technology

 In the following two days, the team visited many high-end medical institutions such as West China Lecheng hospital, Ruijin Hainan hospital and international innovation pharmaceutical and equipment exhibition, and witnessed the great vitality of the "first try" policy - the world's leading innovative medical and equipment treatment scheme synchronized with the international, and is serving patients through "special access", which is not only the opening of the policy, but also the landing of an advanced medical concept of "patient-centered".

 During this trip, QINGDAO AMA Co.,LTD. also participated in the industrial seminar of the Administration Bureau of Lecheng Pioneer District. Fusheng, the director general, attended and delivered a speech, stressing that Lecheng is committed to building an integrated platform of "politics, industry, learning, research and application", clearing obstacles for enterprises and promoting innovative technologies to enter the market steadily. We clearly see that from technology to accessible therapy, we cannot do without policy escort, clinical collaboration and industrial integration. Le Cheng is providing such systematic support.

General manager wuxuetao, the head of arterialnet, made an in-depth analysis of the path of CGT clinical transformation and industrialization. The case of small cell lung cancer shared by Luan Tianyan, director of West China Hospital, and the progress of stem cell therapy for knee osteoarthritis introduced by Yang Wei, general manager of Ruijin Hospital provided a valuable clinical perspective and cooperation inspiration for our company.

Promote knowledge by doing, prosper business by meeting, and move forward firmly.

 Keep moving as you want. This trip to Hainan has put us at the crossroads of China's medical innovation and opening-up. QINGDAO AMA Co.,LTD. will fully absorb the results of the visit, rely on the dialogue and insight established during this visit, accelerate the industrialization and clinical transformation of the "scaffold free cell live tablet" technology, and work with all walks of life to welcome the new future of regenerative medicine.